Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP:a Meta-analysis  

作　　者：Shi-Dan Wang Guo-Ming Zhang 

机构地区：[1]Shenzhen Screening for Retinopathy of Prematurity Cooperative Group [2]Department of Pediatric Retinal Surgery,Shenzhen Eye Hospital,Shenzhen Key Ophthalmic Laboratory,the Second Affiliated Hospital of Jinan University,Shenzhen 518040,Guangdong Province,China

出　　处：《International Journal of Ophthalmology(English edition)》2020年第5期806-815,共10页国际眼科杂志（英文版）

基　　金：Supported by the Basic Discipline Layout Foundation of the Shenzhen Science and Innovation Commission(No.JCYJ20170817112542555)。

摘　　要：AIM:To compare the efficacy and safety between laser therapy and anti-vascular endothelial growth factor(VEGF)agents intravitreal injection monotherapy in type-1 retinopathy of prematurity(ROP)and aggressive posterior retinopathy of prematurity(APROP).METHODS:A systematic literature search was performed in PubMed,Cochrane Library,and Embase for original comparable studies.We included studies that compare laser therapy and intravitreal injections of anti-VEGF agents monotherapy in ROP regardless of languages and publication types.RESULTS:Complication incidence was significantly higher in laser therapy group(OR:0.38;95%CI:0.19-0.75;P=0.005).Spherical equivalent(SE)was higher in laser therapy[weighted mean difference(WMD):2.40,95%CI:0.88-3.93;P=0.002].The time between treatment and retreatment was longer in laser therapy group(WMD:8.45,95%CI:5.35-11.55;P<0.00001).Recurrence incidence(OR:0.97;95%CI:0.45-2.09;P=0.93)and retreatment incidence(OR:1.24;95%CI:0.56-2.73;P=0.59)were similar in two approaches.Subgroup analysis between type-1 ROP and APROP was not significant except SE reported in the included studies(P<0.0001).CONCLUSION:This Meta-analysis outcome indicates anti-VEGF agents are as effective as laser treatment,and safer than laser in type-1 ROP and APROP.The degree of myopia in APROP is higher than type-1 ROP.More randomized controlled trials in large sample size should be conducted in the future.

关 键 词：anti-vascular endothelial growth factor BEVACIZUMAB laser therapy META-ANALYSIS retinopathy of prematurity RECURRENCE RANIBIZUMAB 

分 类 号：R774.1[医药卫生—眼科]